Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 7,000 shares at $22.53 ($150K) on 2012-11-02, disclosed to the SEC on 2012-11-06.
Scheduled sale ($150k) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.42 | 6,800 | $146K | 97.0% |
| 2 | $22.53 | 200 | $5K | 3.0% |
| Total | $21.45 avg | 7,000 | $150K | 100% |
| Filing → |
| THRX | SELL | 2013-08-01 | $256K | — | Filing → |
| THRX | SELL | 2013-05-02 | $236K | — | Filing → |
| THRX | SELL | 2013-02-22 | $155K | — | Filing → |